- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT01326663
Divalproex Sodium for Mood Swings and Alcohol Use Following Head Injury.
A Double Blind Trial Of Divalproex Sodium For Affective Lability And Alcohol Use Following Traumatic Brain Injury
Despite the body's natural healing during the first year after a head injury, many veterans who have suffered even mild brain injuries find themselves easily upset or fearful as they go about their daily lives. While these reactions to the world around them were easily managed before the head injury, they now occur with little or no interruption and are exceedingly difficult to manage. Such reactions include a sense of always being upset or fearful that often makes it difficult to get along with family members, friends, coworkers, and employers. This may lead to broken marriages, unemployment, and even homelessness.
Some people with head injuries try to manage their unmanageable moods by drinking alcohol because it can create a sense of calm. However, alcohol's actions are short in duration. Most find that they have to drink more and more for a similar calming effect, and they soon become dependent on alcohol. This makes working and being part of their families even more difficult.
To treat the unmanageable mood, we tried a medicine called valproate, one that eases mood problems in people without head injury. We gave valproate to head injured persons with mood problems in a "non-blinded" study where both the doctor and the patient knew that the medicine was valproate and both were optimistic that it would work. In a small sample of eighteen people, 85% found mood relief and most of those either stopped drinking alcohol or drank much less than before. However, this might have been because both the doctor and patient were hopeful that the medication would make the patient feel better or because the medicine actually worked.
The only way to know for sure if the medicine works is to perform a study in which people receive either valproate or a sugar pill while neither they nor their doctor know which one they are taking. This is called a double blind study, as proposed here, and will involve nearly three times as many head injured persons as the first study.
If it is successful, this study will show that valproate treatment helps head injured people manage their moods and allows them to return to families, friends, and work. It will also show that they drink alcohol less or not at all, improving their health even further. Then doctors will know that they can use this medicine for large numbers of people who suffer from head injury and help them to lead normal lives. If the outcome of the study shows that the medicine works well, doctors can then use this medicine to treat people with head injury immediately after the study results are published.
Přehled studie
Postavení
Podmínky
Intervence / Léčba
Typ studie
Zápis (Očekávaný)
Fáze
- Nelze použít
Kontakty a umístění
Studijní místa
-
-
Colorado
-
Denver, Colorado, Spojené státy, 80220
- Nábor
- Denver Veteran's Affairs Medical Center
-
Kontakt:
- Brandon Schmidt, MA
- Telefonní číslo: 720-854-4200
-
-
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
- a history of remote (≥ 1 year prior to study enrollment) non-penetrating TBI
- currently using alcohol
- symptoms of affective lability: mood swings, irritability, frustration
Exclusion Criteria:
- a history of bipolar disorder or anxiety disorder prior to any head injury
- a history of head injury in which the cranium was opened either traumatically or surgically
- a history of stroke
- a history of seizure disorder other than those caused by ethanol withdrawal
- evidence of active liver disease
- current diagnosis or past history of major psychosis, the alcohol amnesic syndrome, or any type of dementia
- current suicidal/homicidal ideations
- any medical conditions that would constitute contraindications to treatment with divalproex sodium
- currently taking any medications that are known to affect the metabolism of divalproex sodium
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: Randomizované
- Intervenční model: Paralelní přiřazení
- Maskování: Čtyřnásobek
Zbraně a zásahy
Skupina účastníků / Arm |
Intervence / Léčba |
|---|---|
|
Komparátor placeba: cukrová pilulka
|
|
|
Aktivní komparátor: divalproex sodný
|
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Reduced Affective Lability
Časové okno: Study weeks 1-10
|
The primary analysis addresses our primary hypothesis that treatment with divalproex sodium will lessen affective lability significantly (p<0.05) as compared to placebo.
We will characterize affective lability using discrete variables of presence or extent of symptoms yielded by the Neurobehavioral Rating Scale-Revised (Levin et al., 1990) as well as eight target items from the Agitated Behavior Scale (Bogner et al., 2000).
Average intensity and duration of affective lability will be compared between groups.
|
Study weeks 1-10
|
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Reduced Alcohol Use
Časové okno: Study weeks 1-10
|
The secondary analysis first addresses our secondary hypothesis that treatment with divalproex sodium will lessen quantity and frequency of ethanol use significantly (p<0.05) as compared to placebo in a sample of TBI subjects.
We will characterize drinking using the Time Line Follow-Back for Drugs and Alcohol method, developed by Sobell et al (Sobell et al., 1979).
|
Study weeks 1-10
|
Spolupracovníci a vyšetřovatelé
Sponzor
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Očekávaný)
Dokončení studie (Očekávaný)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Odhad)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další relevantní podmínky MeSH
Další identifikační čísla studie
- PT075168 (Jiný identifikátor: Department of Defense)
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na Medication Trial
-
Duke UniversityNáborTransplantace hematopoetických buněkSpojené státy
-
University of MalayaZatím nenabírámeHypertenze | Dyslipidémie | Diabetes mellitus typu 2Malajsie
-
VA Office of Research and DevelopmentIcahn School of Medicine at Mount Sinai; Weill Medical College of Cornell University a další spolupracovníciDokončeno
-
University of PennsylvaniaNáborSyndrom pálení v ústechSpojené státy
-
Duke Vascular, Inc.UkončenoAneuryzmata břišní aortySpojené státy
-
GE HealthcareDokončeno
-
Memorial Hospital of Rhode IslandNational Heart, Lung, and Blood Institute (NHLBI)DokončenoKoronární onemocnění | Hypercholesterolémie | Primární zdravotní péče | Management, rizikoSpojené státy
-
NYU Langone HealthStaženo
-
Sara FaragDokončenoPoruchy vyprazdňování | Zadržování močiSpojené státy
-
University of PittsburghStaženoAdherence léků | Nežádoucí reakce na drogu | Léky NonadherenceSpojené státy